281 related articles for article (PubMed ID: 33815393)
1. Novel Virus-Like Particle Vaccine Encoding the Circumsporozoite Protein of
Kurtovic L; Wetzel D; Reiling L; Drew DR; Palmer C; Kouskousis B; Hanssen E; Wines BD; Hogarth PM; Suckow M; Jenzelewski V; Piontek M; Chan JA; Beeson JG
Front Immunol; 2021; 12():641421. PubMed ID: 33815393
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis B virus-like particles expressing Plasmodium falciparum epitopes induce complement-fixing antibodies against the circumsporozoite protein.
Kingston NJ; Kurtovic L; Walsh R; Joe C; Lovrecz G; Locarnini S; Beeson JG; Netter HJ
Vaccine; 2019 Mar; 37(12):1674-1684. PubMed ID: 30773400
[TBL] [Abstract][Full Text] [Related]
3. Bacterial superglue generates a full-length circumsporozoite protein virus-like particle vaccine capable of inducing high and durable antibody responses.
Janitzek CM; Matondo S; Thrane S; Nielsen MA; Kavishe R; Mwakalinga SB; Theander TG; Salanti A; Sander AF
Malar J; 2016 Nov; 15(1):545. PubMed ID: 27825348
[TBL] [Abstract][Full Text] [Related]
4. Enhancing protective immunity to malaria with a highly immunogenic virus-like particle vaccine.
Collins KA; Snaith R; Cottingham MG; Gilbert SC; Hill AVS
Sci Rep; 2017 Apr; 7():46621. PubMed ID: 28422178
[TBL] [Abstract][Full Text] [Related]
5. Head-to-Head Comparison of Soluble vs. Qβ VLP Circumsporozoite Protein Vaccines Reveals Selective Enhancement of NANP Repeat Responses.
Khan F; Porter M; Schwenk R; DeBot M; Saudan P; Dutta S
PLoS One; 2015; 10(11):e0142035. PubMed ID: 26571021
[TBL] [Abstract][Full Text] [Related]
6. Optimization of a
Langowski MD; Khan FA; Bitzer AA; Genito CJ; Schrader AJ; Martin ML; Soto K; Zou X; Hadiwidjojo S; Beck Z; Matyas GR; Livingstone MC; Batchelor AH; Dutta S
Proc Natl Acad Sci U S A; 2020 Feb; 117(6):3114-3122. PubMed ID: 31988134
[No Abstract] [Full Text] [Related]
7. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
[TBL] [Abstract][Full Text] [Related]
8. Malaria vaccine candidates displayed on novel virus-like particles are immunogenic and induce transmission-blocking activity.
Chan JA; Wetzel D; Reiling L; Miura K; Drew DR; Gilson PR; Anderson DA; Richards JS; Long CA; Suckow M; Jenzelewski V; Tsuboi T; Boyle MJ; Piontek M; Beeson JG
PLoS One; 2019; 14(9):e0221733. PubMed ID: 31504038
[TBL] [Abstract][Full Text] [Related]
9. Development of a Novel Virus-Like Particle Vaccine Platform That Mimics the Immature Form of Alphavirus.
Urakami A; Sakurai A; Ishikawa M; Yap ML; Flores-Garcia Y; Haseda Y; Aoshi T; Zavala FP; Rossmann MG; Kuno S; Ueno R; Akahata W
Clin Vaccine Immunol; 2017 Jul; 24(7):. PubMed ID: 28515133
[TBL] [Abstract][Full Text] [Related]
10. Strategic Variants of CSP Delivered as SynDNA Vaccines Demonstrate Heterogeneity of Immunogenicity and Protection from
Reeder SM; Bah MA; Tursi NJ; Brooks RC; Patel A; Esquivel R; Eaton A; Jhun H; Chu J; Kim K; Xu Z; Zavala F; Weiner DB
Infect Immun; 2021 Sep; 89(10):e0072820. PubMed ID: 34152830
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of Wild Type and Mutant Hepatitis B Surface Antigen Virus-like Particles (VLPs) in Mice with Pre-Existing Immunity against the Wild Type Vector.
Kingston NJ; Walsh R; Hammond R; Joe CCD; Lovrecz G; Locarnini S; Netter HJ
Viruses; 2023 Jan; 15(2):. PubMed ID: 36851527
[TBL] [Abstract][Full Text] [Related]
12. Circumsporozoite protein as a potential target for antimalarials.
Fernández-Arias C; Mashoof S; Huang J; Tsuji M
Expert Rev Anti Infect Ther; 2015 Aug; 13(8):923-6. PubMed ID: 26081442
[TBL] [Abstract][Full Text] [Related]
13. IgG2 antibodies against a clinical grade Plasmodium falciparum CSP vaccine antigen associate with protection against transgenic sporozoite challenge in mice.
Schwenk R; DeBot M; Porter M; Nikki J; Rein L; Spaccapelo R; Crisanti A; Wightman PD; Ockenhouse CF; Dutta S
PLoS One; 2014; 9(10):e111020. PubMed ID: 25343487
[TBL] [Abstract][Full Text] [Related]
14. Baseline exposure, antibody subclass, and hepatitis B response differentially affect malaria protective immunity following RTS,S/AS01E vaccination in African children.
Ubillos I; Ayestaran A; Nhabomba AJ; Dosoo D; Vidal M; Jiménez A; Jairoce C; Sanz H; Aguilar R; Williams NA; Díez-Padrisa N; Mpina M; Sorgho H; Agnandji ST; Kariuki S; Mordmüller B; Daubenberger C; Asante KP; Owusu-Agyei S; Sacarlal J; Aide P; Aponte JJ; Dutta S; Gyan B; Campo JJ; Valim C; Moncunill G; Dobaño C
BMC Med; 2018 Oct; 16(1):197. PubMed ID: 30376866
[TBL] [Abstract][Full Text] [Related]
15. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine.
Chaudhury S; MacGill RS; Early AM; Bolton JS; King CR; Locke E; Pierson T; Wirth DF; Neafsey DE; Bergmann-Leitner ES
Vaccine; 2021 Feb; 39(6):968-975. PubMed ID: 33431225
[TBL] [Abstract][Full Text] [Related]
16. The effect of immunization schedule with the malaria vaccine candidate RTS,S/AS01E on protective efficacy and anti-circumsporozoite protein antibody avidity in African infants.
Ajua A; Lell B; Agnandji ST; Asante KP; Owusu-Agyei S; Mwangoka G; Mpina M; Salim N; Tanner M; Abdulla S; Vekemans J; Jongert E; Lievens M; Cambron P; Ockenhouse CF; Kremsner PG; Mordmüller B
Malar J; 2015 Feb; 14():72. PubMed ID: 25885325
[TBL] [Abstract][Full Text] [Related]
17. Safety, toxicity and immunogenicity of a malaria vaccine based on the circumsporozoite protein (FMP013) with the adjuvant army liposome formulation containing QS21 (ALFQ).
Cawlfield A; Genito CJ; Beck Z; Bergmann-Leitner ES; Bitzer AA; Soto K; Zou X; Hadiwidjojo SH; Gerbasi RV; Mullins AB; Noe A; Waters NC; Alving CR; Matyas GR; Dutta S
Vaccine; 2019 Jun; 37(29):3793-3803. PubMed ID: 31151801
[TBL] [Abstract][Full Text] [Related]
18. Identification of an Immunogenic Mimic of a Conserved Epitope on the Plasmodium falciparum Blood Stage Antigen AMA1 Using Virus-Like Particle (VLP) Peptide Display.
Crossey E; Frietze K; Narum DL; Peabody DS; Chackerian B
PLoS One; 2015; 10(7):e0132560. PubMed ID: 26147502
[TBL] [Abstract][Full Text] [Related]
19. Heterologous prime-boost immunization in rhesus macaques by two, optimally spaced particle-mediated epidermal deliveries of Plasmodium falciparum circumsporozoite protein-encoding DNA, followed by intramuscular RTS,S/AS02A.
Walsh DS; Gettayacamin M; Leitner WW; Lyon JA; Stewart VA; Marit G; Pichyangkul S; Gosi P; Tongtawe P; Kester KE; Holland CA; Kolodny N; Cohen J; Voss G; Ballou WR; Heppner DG
Vaccine; 2006 May; 24(19):4167-78. PubMed ID: 16574282
[TBL] [Abstract][Full Text] [Related]
20. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
Chichester JA; Green BJ; Jones RM; Shoji Y; Miura K; Long CA; Lee CK; Ockenhouse CF; Morin MJ; Streatfield SJ; Yusibov V
Vaccine; 2018 Sep; 36(39):5865-5871. PubMed ID: 30126674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
